Supreme Court Dismisses Challenge to Abortion Pill Approval
Unanimous ruling keeps mifepristone accessible but leaves door open for future legal battles
- The Supreme Court ruled that the plaintiffs lacked standing to challenge the FDA's mifepristone approval.
- The ruling means mifepristone remains available, but the court did not address the drug's safety or FDA's decision.
- Legal experts warn that new challenges to mifepristone are likely, potentially using different plaintiffs or legal strategies.
- The decision has significant implications for medication abortion access and ongoing state-level abortion restrictions.
- Public opinion largely supports maintaining access to mifepristone, with many voters viewing the ruling favorably.













































































































































































